News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2022
-
May 11, 2022
Roche Announces Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
[PDF 166KB] -
May 10, 2022
Together with Roche, Chugai Pledges to Extend Commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
[PDF 311KB] -
Apr 28, 2022
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 223KB] -
Apr 25, 2022
Chugai Announces 2022 1st Quarter Results
[PDF 974KB] -
Apr 25, 2022
Organizational and Personnel Changes
[PDF 437KB] -
Apr 25, 2022
F. Hoffmann-La Roche Announces First Quarter Sales 2022
[PDF 178KB] -
Apr 21, 2022
Chugai Adopts Snowflake Data Cloud to Accelerate Use of Internal Data across Company
Snowflake Brings its Global Experience and Track Record in Healthcare and Life Sciences to Japan for First Time [PDF 409KB] -
Apr 04, 2022
U.S. FDA Grants Priority Review to Chugai’s Actemra/RoActemra for the Treatment of COVID-19 in Hospitalized Adults
[PDF 385KB] -
Mar 29, 2022
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 181KB] -
Mar 28, 2022
Chugai Obtains Regulatory Approval for Vabysmo, the First Bispecific Antibody in Ophthalmology, for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
[PDF 379KB] -
Mar 28, 2022
Maruho Obtained Regulatory Approval for Mitchga, the First Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis
[PDF 360KB] -
Mar 28, 2022
Chugai Obtains Regulatory Approval for Perjeta and Herceptin for Additional Indication of HER2-Positive Colorectal Cancer
[PDF 438KB] -
Mar 22, 2022
Chugai Selected as a “Nadeshiko Brand”
--The proactive approach to diversity is highly evaluated by external organizations-- [PDF 326KB] -
Mar 17, 2022
Notice of the Settlement of Patent Infringement Litigation
[PDF 90KB] -
Mar 14, 2022
Humanitarian Donation for Ukraine
[PDF 329KB] -
Mar 10, 2022
Personnel Changes
[PDF 245KB] -
Mar 07, 2022
Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Chronic Lymphocytic Leukemia
[PDF 196KB] -
Feb 24, 2022
Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit concerning Edirol Capsules
[PDF 206KB] -
Feb 14, 2022
Chugai Reorganizes Business Operation in China to Further Strengthen the Foundation of Overseas Business
[PDF 292KB] -
Feb 03, 2022
Chugai Announces 2021 Full Year Results and Forecasts for 2022
[PDF 924KB] -
Feb 03, 2022
Personnel Changes
[PDF 491KB] -
Feb 03, 2022
Notice of Changes in Representative Directors and Directors
[PDF 230KB] -
Feb 03, 2022
Notice of Distribution of Retained Earnings
[PDF 104KB] -
Feb 03, 2022
Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year
[PDF 100KB] -
Feb 03, 2022
Notice of Partial Amendments to the Articles of Incorporation
[PDF 140KB] -
Feb 03, 2022
F. Hoffmann-La Roche Announces Financial Results for fiscal 2021
[PDF 178KB] -
Jan 21, 2022
Chugai’s Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia in Japan
[PDF 350KB]